One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: Predictors of hemodynamic and clinical response

Clinical Research in Cardiology

Volumn 96, Issue 12, 2007, Pages 864-873

  Faber, Lothar ^a   Welge, Dirk ^a   Fassbender, Dieter ^a   Schmidt, Henning K ^a   Horstkotte, Dieter ^a   Seggewiss, Hubert ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Leopoldina Hospital   (Germany)

Author keywords

Hypertrophic obstructive cardiomyopathy; Left ventricular outflow tract gradient; Myocardial contrast echocardiography; Percutaneous septal ablation

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VERAPAMIL;

ADULT; AGE DISTRIBUTION; ARTICLE; CATHETER ABLATION; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; DEFIBRILLATION; FEMALE; FOLLOW UP; HEART HEMODYNAMICS; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PACEMAKER; PERCUTANEOUS TRANSLUMINAL SEPTUM MYOCARDIAL ABLATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HEMODYNAMICS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; SOLVENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 36448949386     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0578-9     Document Type: Article

References (33)

1. Spirito P, Seidman CE, Mc Kenna WJ, Maron BJ (1997) The managemant of hypertrophic cardiomyopathy. New Engl J Med 336:775-785
2. Wigle DE, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 92:1680-1692
3. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
4. Kimmelstiel CD, Maron BJ (2004) Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 109:452-456
5. Knight CJ, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 95:2075-2081
6. Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 18:846-851
7. ACC/ESC (2003) Clinical Expert Consensus Document on HCM. Eur Heart J 24:1965-1991
8. Braunwald E (1997) Induced septal infarction: A new strategy for hypertrophic obstructive cardiomyopathy. Circulation 95:1981
9. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure- guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846-853
10. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 98:2415-2421
11. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH 3rd, Nagueh SF (2001) Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 37:208-214
12. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn H (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 20:1342-1354
13. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 93:23-31
14. Lakkis NM, Nagueh SF, Kleiman NS, Killip DM, He ZX, Verani M, Roberts R, Spencer WH III (1998) Echocardiography- guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750-1755
15. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252-258
16. Seggewiss H (2001) Current status of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep 3:160-166
17. Spencer WH 3rd, Roberts R (2000) Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry. Circulation 102:600-601
18. Faber L, Seggewiss H, Ziemssen P (2000) Targeting percutaneous transluminal septal ablation for HOCM by intra-procedural echocardiographic monitoring. J Am Soc Echocardiogr 13:1074-1079
19. Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for HOCM: Long-term follow-up in the first series of 25 patients. Heart 83:326-331
20. Heric B, Lytle BW, Miller OP (1995) Surgical management of hypertrophic obstructive cardiomyopathy. J Thor Cardiovasc Surg 110:195-208
21. Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wochenschr 125:1940-1949
22. Schulte HD, Bircks W, Lösse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM). Z Kardiol 76 (Suppl 3):145-151
23. Robbins RC, Stinson EB, Daily PO (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586-594
24. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat M, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in HCM: Identification of high risk patients. J Am Coll Cardiol 36:2212-2218
25. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL Jr, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-1713
26. Maron BJ, Nishimure RA, McKenna WJ et al (1999) Assessment of permanent dual-chamber pacing as treatment for drug refractory patients with obstructive HCM (M-PATHY). Circulation 99:2927-2933
27. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik JA, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1707-1710
28. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994-2000
29. Chang SM, Lakkis NM, Franklin J, Spencer WHIII, Nagueh SF (2004) Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109:824-827
30. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie. Z Kardiol 92:39-45
31. Qin JX, Shiota T, Lever HM, Asher CR, Popovic ZB, Greenberg NL, Agler DA, Drinko JK, Smedira NG, Tuzcu EM, Lytle BW, Thomas JD (2004) Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 93:171-175
32. Veselka J, Duchonova R, Prochazkova S, Palenickova J, Sorajja P, Tesar D (2005) Effects of varying dosing in pecutaneous septal ablation for obstructive HCM on early hemodynamic changes. Am J Cardiol 95:675-678
33. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L (2007) Long- Term Follow-up After Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. Clin Res Cardiol (submitted)